Teerin Liewluck, M.D.

Contact Us for the Latest Status

• A Post-Authorization Safety Study (PASS) to Assess Long-term Safety in Patients with Pompe Disease Treated with Avalglucosidase alfa in the Real-World Setting: the SAVANT (Safety assessment of AValglucosidase Alfa as a Novel Treatment) study Rochester, Minn.

  The purpose of this study will provide important londitdinal data to charactererize the long-tem profile of avalglucosidase in alfa use in the real world setting.